Literature DB >> 10764435

Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer.

T C Chang1, C H Lai, J H Hong, S Hsueh, K G Huang, H H Chou, C J Tseng, C S Tsai, J T Chang, C T Lin, H H Chang, P J Chao, K K Ng, S G Tang, Y K Soong.   

Abstract

PURPOSE: To compare the efficacy of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy with that of radiotherapy (R/T) for bulky early-stage cervical cancer. PATIENTS AND METHODS: Women with previously untreated bulky (primary tumor >/= 4 cm) stage IB or IIA non-small-cell carcinoma of the uterine cervix were randomly assigned to receive either cisplatin 50 mg/m(2) and vincristine 1 mg/m(2) for 1 day and bleomycin 25 mg/m(2) for 3 days for three cycles followed by radical hysterectomy (NAC arm) or receive primary pelvic radiotherapy only (R/T arm). The ratio of patient allocation was 6:4 for the NAC and R/T arms. Women with enlarged para-aortic lymph nodes on image study were ineligible unless results of cytologic or histologic studies were negative.
RESULTS: Of the 124 eligible patients, 68 in the NAC arm and 52 in the R/T arm could be evaluated. The median duration of follow-up was 39 months. Thirty-one percent of patients in the NAC arm and 27% in the R/T arm had relapse or persistent diseases after treatment, and 21% in each group died of disease. Estimated cumulative survival rates at 2 years were 81% for the NAC arm and 84% for the R/T arm; the 5-year rates were 70% and 61%, respectively. There were no significant differences in disease-free survival and overall survival.
CONCLUSION: NAC followed by radical hysterectomy and primary R/T showed similar efficacy for bulky stage IB or IIA cervical cancer. Further study to identify patient subgroups better suited for either treatment modality and to evaluate the concurrent use of cisplatin and radiation without routine hysterectomy is necessary.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764435     DOI: 10.1200/JCO.2000.18.8.1740

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

Review 1.  Antiangiogenics and immunotherapies in cervical cancer: an update and future's view.

Authors:  Daniela Luvero; Francesco Plotti; Salvatore Lopez; Giuseppe Scaletta; Stella Capriglione; Roberto Montera; Gianina Antonelli; Sara Ciuffreda; Raffaella Carassiti; Alice Oliveti; Roberto Angioli
Journal:  Med Oncol       Date:  2017-05-05       Impact factor: 3.064

Review 2.  The role of radical hysterectomy and neoadjuvant chemotherapy in carcinoma of the cervix.

Authors:  David H Moore
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

3.  Induction Chemotherapy Followed by Concurrent Chemoradiation in the Management of Different Stages of Cervical Carcinoma: 5-year Retrospective Study.

Authors:  Kamlesh Kumar Harsh; Akhil Kapoor; Murali Paramanandhan; Satya Narayan; Ramesh Purohit; Pramila Kumari; Mukesh Kumar Singhal
Journal:  J Obstet Gynaecol India       Date:  2015-05-01

4.  Defining the Role of Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Cancer Cervix: A Meta-analysis of Phase III Trials.

Authors:  Mohammed A Osman
Journal:  J Obstet Gynaecol India       Date:  2015-05-16

5.  Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer.

Authors:  Kyung-Do Ki; Jong-Min Lee; Seon-Kyung Lee; Seo-Yun Tong; Chu-Yeop Huh; Jung-Kyu Ryu; Kyo-Young Kim
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

6.  Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women.

Authors:  Shoji Kaku; Kentaro Takahashi; Yoshitaka Murakami; Shirou Wakinoue; Tetsuya Nakagawa; Yoshihiko Shimizu; Nobuyuki Kita; Yoichi Noda; Takashi Murakami
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

Review 7.  Cervical cancer.

Authors:  Pierre Leonard Martin-Hirsch; Nicholas James Wood
Journal:  BMJ Clin Evid       Date:  2011-07-27

8.  Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer.

Authors:  Youn Seok Choi; Jeong-Im Sin; Ju Hyun Kim; Gi Won Ye; Im Hee Shin; Tae Sung Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

9.  Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.

Authors:  Roberto Angioli; Francesco Plotti; Daniela Luvero; Alessia Aloisi; Federica Guzzo; Stella Capriglione; Corrado Terranova; Carlo De Cicco Nardone; Pierluigi Benedetti-Panici
Journal:  Tumour Biol       Date:  2014-03

10.  Long-term follow-up of neoadjuvant intraarterial chemotherapy using an original four-lumen double-balloon (4L-DB) catheter for locally advanced uterine cervical cancer.

Authors:  Yoshito Terai; Masanori Kanemura; Hiroshi Sasaki; Satoshi Tsunetoh; Yoshimichi Tanaka; Yoshiki Yamashita; Kazuhiro Yamamoto; Isamu Narabayashi; Masahide Ohmichi
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.